Thetis Pharmaceuticals, LLC

167 Old Post Road 
Southport, CT 06890
203.254.3333

Thetis is a drug development company that is advancing TP101, a novel, first-line therapy for type 2 diabetes. TP101 is a new molecular entity that chemically combines metformin, the standard of care in type 2 diabetes, with the principal component from omega-3 polyunsaturated fatty acids. TP101 uniquely targets both glycemic and lipid control in diabetes patients and, for the first time, offers prospects for addressing the high incidence of cardiovascular complications, a major risk factor in type 2 diabetic and pre-diabetic patients. The company expects to begin clinical studies with TP101 in 2012, an exceptionally rapid timeline made possible by certain regulatory efficiencies associated with the metformin / omega-3 chemical composition of the drug candidate.